Category Archives: Cell Biology

Brain Development and Disorder Research Receives $1.5 Million NSF Boost – USC Viterbi School of Engineering

A 15-day-old brain organoid: Department of Biomedical Engineering researchers are partnering with Keck School of Medicine of USC to improve the creation of these materials, which can help us better understand brain development and disorders.Image/ Giorgia Quadrato

The human brain is an incredibly complex organ to study in its living tissue form. Researchers cannot experiment on human tissue directly, and animal models are often too different to human physiology to be effective.

For this reason, in the last decade, neurological research has been increasingly turning to brain-on-a-chip organoid models to give researchers living examples to demonstrate brain development, and how to effectively treat brain diseases and disorders. Organoids are grown out of stem cells into new cell clusters that mimic the structure of and features of a whole organ, such as the brain.

Co-principal investigator Megan McCain from the USC Viterbi Department of Biomedical Engineering will partner with fellow co-principal investigators Giorgia Quadrato and Leonardo Morsut in the Department of Stem Cell Biology and Regenerative Medicine at the Keck School of Medicine of USC on a four year, $1.5m NSF-funded project to vastly improve the process of developing brain organoids. The project aims to make the end products more consistent and reliable as tools for brain researchers.

McCain is the Chonette Early Career Chair and assistant professor of biomedical engineering at USC Viterbi. She said that one of the biggest hurdles in the current process of organoid creation was their lack of uniformity.

Researchers start with a small group of human stem cells, and then give them some chemical cues to direct their development into brain tissue, but ultimately, the cells are mostly left to their own devices, so they often grow very randomly, McCain said. They divide and differentiate into other cell types in a somewhat haphazard process. So if you make ten organoids, all ten of them will look slightly different.

A brain organoid in a fluidic device from the labs of Megan McCain and Giorgia Quadrato.

McCain said it was this issue that could be detrimental to the accuracy of using organoids in certain types of research, such as the testing of therapeutics and how the brain responds to these drugs, and that organoids needed to be more uniform and reproducible in order to be more effective tools.

Drug testing with organoids today is very challenging because it is hard to separate the effect of the drug from the inherent variability of the organoids themselves, McCain said.

Morsut said that his part of the project involves developing synthetic molecular tools to simplify the analysis of what happens during the formation of brain organoids in a laboratory setting.

The normal molecules that are used by the cells to self-organize, as well as to make decisions, are linked in very complex networks, and we need artificial tools to tease apart the contributions of these different components, Morsut said. The challengeand the exciting partis to use these tools to explain the remarkable phenomenon of self-organization.

McCain said her lab will focus on the device sidethe organ-on-chipand make microfluidic components for growing and studying organoids under more defined conditions.

This will likely improve reproducibility and possibly organoid maturity, which is another major bottleneck, McCain said.

In order to do this, McCains lab will be repurposing a microfluidic device that they previously used to help explanted zebrafish hearts to remain alive longer and regenerate, while also live-imaging the process.

The device, when applied to brain organoids, will constrain the cells in chambers where the team can run experiments through them in a more controlled way, to see if this improves the consistency of the end product.

And we will also be able to image and monitor their reproducibility by putting them in this little device where theyre all growing in the same configuration, McCain said.

Quadrato, an expert in brain organoids, said she was excited about the collaboration, because a multidisciplinary approach was needed to improve the relevance of current organoids.

One way to improve brain organoid-to-organoid reproducibility is to expose them to small molecules to direct differentiation of the stem cells, Quadrato said.

She said that these small molecules unfortunately sometimes have problematic side effects, such as impairing the survival of other non-neural cell types, or skewing tests of potential treatments for brain diseases and disorders.

In our proposal, we suggest an alternative strategy to increase brain organoid reproducibility that does not cause these side effects, and therefore can be used to create organoids to accurately model disease, Quadrato said.

Further information about the project is available from the National Science Foundation.

Here is the original post:
Brain Development and Disorder Research Receives $1.5 Million NSF Boost - USC Viterbi School of Engineering

Zavala Named One of the Most Inspiring Hispanic/Latinx Scientists in America – CSUN Today

Our aim in assembling these names is to put an end to the harmful myth that there are not enough diverse scientists to give seminars, serve as panelists or fill scientific positions, the authors wrote. We hope it will help to change the perception of what a scientist looks like and makes our collective image more representative of society at large.

Zavala, who has taught at CSUN since 1988, was the first Mexican American woman in the country to earn a Ph.D. in botany. Since coming to CSUN, she has played an integral part in building the national reputation of CSUNsDepartment of Biologyas a place where students, particularly those from underserved communities, thrive and successfully pursue advanced degrees at top-tier research institutions.

She has served as director of CSUNs Maximizing Access to Research Careers Undergraduate Student Training in Academic Research (MARC U-STAR) program since 1990 and Research Initiatives for Scientific Enhancement (RISE) since 1993. Her work as a mentor and advocate for countless students who have gone through these programs earned her recognition from the White House. In 2000, Zavala received the Presidential Award for Excellence in Science, Mathematics and Engineering Mentoring from former President Bill Clinton. And in 2017,Zavala was named the first Latina Fellow of the American Society of Cell Biologyin its 57-year history.

She also oversees CSUNs work as one of three institutions sharing a first-of-its-kind $3 million, five-year grant from the National Science Foundation to create aHispanic-Serving Institutions(HSI) Resource Hub. The hub is charged with reaching out to colleges and universities across the country to build partnerships that will support STEM education, increase STEM research and education capacity at HSIs, and encourage the implementation of cutting-edge training.

Zavalas research focuses on the manipulation of genes as a way to improve plant productivity by enhancing root growth. She also is studying ways to make beans more nutritious.

In addition to being a Fellow of the American Society of Cell Biology, she is also a Fellow of the American Association for the Advancement of Science and, in 2016, became the first Latina Fellow of the American Society of Plant Biologists.

To be named a Fellow is a recognition of your research and the contributions you have made to a particular field of study, Zavala said in 2017. Its nice recognition from your peers. But I am looking forward to the time when Im not the first, but one of several Latina Fellows.

More:
Zavala Named One of the Most Inspiring Hispanic/Latinx Scientists in America - CSUN Today

Singapore scientists discover immune pathway that causes immunodeficiency – BSA bureau

The novel pathway can be a target for liver disease and cancer drugs that failed trials due to inflammatory side effects

Scientists from Singapores A*STARs Institute of Molecular and Cell Biology (IMCB), in collaboration with doctors from KK Womens and Childrens Hospital (KKH), have discovered a new immune pathway based on an investigation of severe immunodeficiency caused by a novel mutation in the NFKBIA gene. The findings were published inThe Journal of Clinical Investigation.

A recent investigation with a rare primary immunodeficiency disease involving a two-week old infant with recurrent infections alongside lung, skin and liver damage instigated the discovery. Scientists at A*STAR identified a new genetic variant in NFKBIA that changed the levels of soluble proteins called cytokines, produced by white blood cells to drive inflammation. Abnormally high production of one cytokine, IL-1, was identified as the key derangement. Crucially, the clinical team was able suppress the patients disease by rational administration of the IL-1-blocking drug, Anakinra, based on these scientific results.

The research team, along with Singapore Immunology Network (SIgN) discovered a previously unknown pathway, which controls IL-1 production. By replicating the mutation in pre-clinical and cellular models, experimental results conclusively showed that the patients genetic variant was the cause of IL-1 hyper-production, and hence the disease. These findings have implications for the development of treatments against liver disease and cancer that target this novel pathway.

While other mutations in NFKBIA have been reported before to cause disease, this mutation has never before been identified. It is the only mutation in which hyper-production of IL-1, severe liver cholestasis and systemic inflammation were documented. The research team believes the mutation limits immune responses via the suppression of many pro-inflammatory cytokines. Yet at the same time, it causes over-production of IL-1, leading to liver damage and inflammation. Using this bedside-to-bench approach of identifying the underlying genetic causes of immunodeficiency diseases, previously unknown pathways which control immune responses can be revealed. These then serve as targets for personalised treatment strategies," said Dr John Connolly, a Research Director at IMCB and co-corresponding author of the study.

The research team will further examine which new mediators are responsible for controlling IL-1 production by this genetic variant, given that this regulatory association between the protein encoded in NFKBIA and IL-1 was not observed previously. As this novel pathway has also been a popular target for cancer drugs that failed trials due to inflammatory side effects, the team will investigate whether these new mediators are responsible for the failure of these drugs, and determine if the side effects can be circumvented.

Image Caption:Staining for the signalling protein NFB (green) in skin cells from a healthy individual (left) and the patient (right) after immune stimulation. The patients novel NFKBIA variant impairs entry of NFB into nucleus (blue). This defect led to changes in cytokine production, resulting in both immunodeficiency and multi-organ damage.

Continue reading here:
Singapore scientists discover immune pathway that causes immunodeficiency - BSA bureau

Global Laser Capture Microdissection Market Will Experience A Noticeable Growth During The Forecast Period 2019-2026||Indivumed GmbH(Germany), AvanSci…

GlobalLaser Capture Microdissection Marketis expected to rise from its initial estimated value of USD 101.3611 million in 2018 to an estimated value of USD 251.14 million by 2026, registering a CAGR of 12.01% in the forecast period of 2019-2026. This rise in market value can be attributed to the increasing applications in pharmaceuticals, hospitals and research and development

Get Sample Copy Of This Report @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-laser-capture-microdissection-market

Few of the major competitors currently working in the Laser Capture Microdissection market areMolecular Machines & Industries(Germany), Danaher (U.S.) , Thermo Fisher Scientific, Inc. (U.S.), ZEISS International(Germany) , DENOVA Sciences Pte Ltd. (Singapore.), Indivumed GmbH(Germany), AvanSci Bio (US), Avant Diagnostics, Inc.(US), Ocimum Biosolutions (India), 3DHISTECH Ltd.( Hungary), Biocompare (Canada)., BioTechniques(UK), MIA Cellavie Inc. (Canada), CaresBio Laboratory LLC (US), Bio-Rad Laboratories, Inc.(US), genedrive plc (UK), Promega Corporation(US), VitroVivo Biotech(India) and Precision MicroFab LLC (US) among others.

Insights of the report

Key Developments in the Market:

Inquire Regarding This Report @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-laser-capture-microdissection-market

Segmentation: Global Laser Capture Microdissection Market

By Product

(Consumables, Reagents and Media, Assay kits, Other consumables, Instruments, Software and Services),

System type

(Ultraviolet lcm, Infrared lcm, Ultraviolet and Infrared lcm, Immunofluorescence lcm),

Application

(research and development, molecular biology, cell biology, forensic science, diagnostics, other applications),

End user

(Academic and Government Research Institutes, Hospitals, Pharmaceutical and Biotechnology companies, Contract Research Organizations (CROS)),

Geography

(North America, South America, Europe, Asia-Pacific, Middle East and Africa)

Market Drivers

Market Restraints

To know more about thestudy@https://www.databridgemarketresearch.com/reports/global-laser-capture-microdissection-market

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchTel: +1-888-387-2818Email:Corporatesales@databridgemarketresearch.com

Continue reading here:
Global Laser Capture Microdissection Market Will Experience A Noticeable Growth During The Forecast Period 2019-2026||Indivumed GmbH(Germany), AvanSci...

Investigations of Deceased COVID-19 Patients Reveal Lung Damage Caused by Persistence of Abnormal Cells – SciTechDaily

Investigations of deceased COVID-19 patients have shed light on possible lung damage caused by the virus.

The study, published today (November 3, 2020) in The Lancets eBioMedicine, by Kings College London in collaboration with University of Trieste and the International Centre for Genetic Engineering and Biology in Italy, shows the unique characteristics to the SARS-CoV-2 virus and may explain why patients suffer from long COVID.

Patients with COVID-19 can experience symptoms such as blood clotting and loss of smell and taste. Some who survive the infection can experience the effects of the disease for months known as long COVID with a feeling of fatigue and lack of breath. There have been a limited number of studies that have analyzed the organs of COVID-19 patients which means the characteristics of the disease are still largely unknown.

Researchers analyzed the organs of 41 patients who died of COVID-19 at the University Hospital of Trieste, Italy, from February to April 2020, at the start of the pandemic. The team took lung, heart, liver, and kidney samples to examine the behavior of the virus.

Findings show extensive lung damage in most cases, with patients experiencing profound disruption of the normal lung structure and the transformation of respiratory tissue into fibrotic material.

Almost 90% of patients showed two additional characteristics that were quite unique to COVID-19 compared to other forms of pneumonia. First, patients showed extensive blood clotting of the lung arteries and veins (thrombosis). Second, several lung cells were abnormally large and had many nuclei, resulting from the fusion of different cells into single large cells. This formation of fused cells (syncytia) is due to the viral spike protein, which the virus uses to enter the cell. When the protein is present on the surface of cells infected by the COVID-19 virus, it stimulates their fusion with other normal lung cells, which can be a cause for inflammation and thrombosis.

Additionally, research showed the long-term persistence of the viral genome in respiratory cells and in cells lining the blood vessels, along with the infected cell syncytia. The presence of these infected cells can cause the major structural changes observed in lungs, which can persist for several weeks or months and could eventually explain long COVID.

The study found no overt signs of viral infection or prolonged inflammation detected in other organs.

Professor Mauro Giacca, at the British Heart Foundation Centre at Kings College London, said: These findings are very exciting. The findings indicate that COVID-19 is not simply a disease caused by the death of virus-infected cells but is likely the consequence of these abnormal cells persisting for long periods inside the lungs.

The team is now actively testing the effect of these abnormal cells on blood clotting and inflammation and are searching for new drugs that can block the viral spike protein which causes cells to fuse.

Reference: Persistence of viral RNA, pneumocyte syncytia and thrombosis are hallmarks of advanced COVID-19 pathology by Rossana Bussani, Edoardo Schneider, Lorena Zentilin, Chiara Collesi, Hashim Ali, Luca Braga, Maria Concetta Volpe, Andrea Colliva, Fabrizio Zanconati, Giorgio Berlot and Furio Silvestri, 3 November 2020, eBioMedicine.DOI: 10.1016/j.ebiom.2020.103104

See the original post:
Investigations of Deceased COVID-19 Patients Reveal Lung Damage Caused by Persistence of Abnormal Cells - SciTechDaily

Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting – GlobeNewswire

Four Oral Presentations Covering iPSC-derived Cell-based Cancer Immunotherapy Pipeline Accepted for Presentation

Company to Host Investor Event on Friday, December 4

SAN DIEGO, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that four oral and eight poster presentations for the Companys induced pluripotent stem cell (iPSC) product platform were accepted for presentation at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition being held virtually from December 5-8, 2020.

Accepted abstracts include a clinical case study of a patient treated with FT596 at the first dose level (30million cells) as a monotherapy in the Companys Phase 1 clinical trial for the treatment of relapsed / refractory B-cell lymphoma (NCT04245722). FT596 is the Companys universal, off-the-shelf, chimeric antigen receptor (CAR) natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with three anti-tumor functional modalities: a proprietary CAR optimized for NK cell biology that targets CD19 (CAR19); a novel high-affinity, non-cleavable CD16 (hnCD16) Fc receptor that enhances antibody-dependent cellular cytotoxicity (ADCC); and an IL-15 receptor fusion (IL-15RF) that augments NK cell activity. The accepted abstracts are available online through the ASH conference website (www.hematology.org/Annual-Meeting/Abstracts/).

In addition, the Company plans to host a virtual investor event entitled The Power of hnCD16 to highlight the unique therapeutic features and functionality of its novel hnCD16 Fc receptor, a core component incorporated in its iPSC-derived NK cell product candidates. The Companys hnCD16 Fc receptor is designed to maximize ADCC, a potent anti-tumor mechanism by which NK cells recognize, bind and kill antibody-coated cancer cells, through enhanced binding to tumor-targeting antibodies and prevention of down-regulation commonly observed in cancer patients. Scientists from the Company have shown in a peer-reviewed publication (Blood. 2020;135(6):399-410) that hnCD16 iPSC-derived NK cells, compared to peripheral blood NK cells, elicit a more durable anti-tumor response and extend survival in combination with anti-CD20 monoclonal antibodies in an in vivo xenograft mouse model of human lymphoma.

Oral Presentations

Poster Presentations

About Fate Therapeutics iPSC Product PlatformThe Companys proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with other cancer treatments. Human iPSCs possess the unique dual properties of unlimited self-renewal and differentiation potential into all cell types of the body. The Companys first-of-kind approach involves engineering human iPSCs in a one-time genetic modification event and selecting a single engineered iPSC for maintenance as a clonal master iPSC line. Analogous to master cell lines used to manufacture biopharmaceutical drug products such as monoclonal antibodies, clonal master iPSC lines are a renewable source for manufacturing cell therapy products which are well-defined and uniform in composition, can be mass produced at significant scale in a cost-effective manner, and can be delivered off-the-shelf for patient treatment. As a result, the Companys platform is uniquely capable of overcoming numerous limitations associated with the production of cell therapies using patient- or donor-sourced cells, which is logistically complex and expensive and is subject to batch-to-batch and cell-to-cell variability that can affect clinical safety and efficacy. Fate Therapeutics iPSC product platform is supported by an intellectual property portfolio of over 300 issued patents and 150 pending patent applications.

About Fate Therapeutics, Inc.Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for cancer and immune disorders. The Company has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its proprietary induced pluripotent stem cell (iPSC) product platform. The Companys immuno-oncology product candidates include natural killer (NK) cell and T-cell cancer immunotherapies, which are designed to synergize with well-established cancer therapies, including immune checkpoint inhibitors and monoclonal antibodies, and to target tumor-associated antigens with chimeric antigen receptors (CARs). The Companys immuno-regulatory product candidates include ProTmune, a pharmacologically modulated, donor cell graft that is currently being evaluated in a Phase 2 clinical trial for the prevention of graft-versus-host disease, and a myeloid-derived suppressor cell immunotherapy for promoting immune tolerance in patients with immune disorders. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit http://www.fatetherapeutics.com.

Forward-Looking StatementsThis release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 including statements regarding the Companys clinical studies and preclinical research and development programs. These and any other forward-looking statements in this release are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risk that results observed in prior studies of its product candidates, including preclinical studies and clinical trials of any of its product candidates, will not be observed in ongoing or future studies involving these product candidates, and the risk that the Company may cease or delay preclinical or clinical development of any of its product candidates for a variety of reasons (including requirements that may be imposed by regulatory authorities on the initiation or conduct of clinical trials or to support regulatory approval, difficulties or delays in subject enrollment in current and planned clinical trials, difficulties in manufacturing or supplying the Companys product candidates for clinical testing, and any adverse events or other negative results that may be observed during preclinical or clinical development). For a discussion of other risks and uncertainties, and other important factors, any of which could cause the Companys actual results to differ from those contained in the forward-looking statements, see the risks and uncertainties detailed in the Companys periodic filings with the Securities and Exchange Commission, including but not limited to the Companys most recently filed periodic report, and from time to time in the Companys press releases and other investor communications.Fate Therapeutics is providing the information in this release as of this date and does not undertake any obligation to update any forward-looking statements contained in this release as a result of new information, future events or otherwise.

Contact:Christina TartagliaStern Investor Relations, Inc.212.362.1200christina@sternir.com

See the original post:
Fate Therapeutics Announces Twelve Presentations at the 2020 ASH Annual Meeting - GlobeNewswire

In-country genetic changes of coronavirus mapped by scientists – University World News

GHANA

In an email exchange with Quashie to explain a collaborative research project on COVID-19, he said they were also able to identify groups of individuals with the same virus in order to identify which types of the virus are circulating in a country because the various types have differing levels of transmissibility and pathogenicity.

The research was conducted at the West African Centre for Cell Biology of Infectious Pathogens and the Noguchi Memorial Institute for Medical Research (NMIMR) of the University of Ghana.

Quashie, who had earlier presented the findings of the study during a webinar, said because of the quality of their work, they were able to actually track and link the different samples to each other and see which samples likely had similar ancestry.

We were able to identify unique substitutions or genetic changes, which were identified in Ghana and have either not been identified elsewhere or are known stochastic [stochastic refers to a pattern that may be analysed statistically, but may not be predicted precisely] mutations that occur in-country, Quashie said.

Transmission pathway followed

The study also showed about 20% of people living in Accra and in Kasoa, totalling about 2 million, may have been exposed to COVID-19. The study was conducted in public places including municipal markets and lorry stations in Accra and Kasoa, shopping malls in Accra, and COVID-19 testing centres and other research institutions or health centres in Accra.

The researchers used a pre-validated antibody rapid diagnostic test (RDT), and were able to determine exposure to SARS-CoV-2, by detecting COVID-19 antibodies in blood samples taken from 1,305 participants. They said these tests were only able to detect exposure to the virus with about 70% accuracy because antibodies wane after some time and might be hard to detect in some individuals.

Dr Yaw Bediako, a research fellow at WACCBIP, said these were somewhat cautionary results, adding that, we know these things can switch in an instant. So we have to be vigilant and we have to be aware that COVID-19 is, indeed, circulating freely in our country and [that] our current testing protocols, which are focused on symptomatic people, will only capture a very small fraction.

Analysing the genetic structure of various strains of the virus, the scientists also found evidence of transmission from the Greater Accra Region, through the Central Region, to the Western Region. The most transmissible variants, according to the data, were found in Ayawaso, a suburb of Accra, which was a hotbed for the disease when it first broke out in the country.

People in lower economic brackets worse off

They said the findings suggested that people in lower economic brackets are more exposed and have higher levels of previous SARS-CoV-2. Results of the extent of antibody presence in the community sampled in the study showed that the exposure rate was higher among people tested at the markets and lorry stations (about 27%) than those at the malls (around 9%). The study also showed that differences in socioeconomic status could determine risk of exposure to the virus.

Having a higher level of education and a high level of income also significantly reduce your risk of being exposed compared to those who have lower levels of education and those who earn low incomes. We also found that individuals working in the informal sector are at a two-fold increased risk of being exposed, said Quashie.

Kofi Bonney, a senior research fellow at NMIMR, said these results were to be expected, adding that, I even expected that a higher percentage would have been recorded, especially from the markets. We saw how they were loosely keeping to the protocols that we're supposed to be adhering to. People are now thinking that we are out of the woods, but we are not there yet. The virus is still circulating, and we need to be wary of that and adhere to the protocols strictly. Otherwise, what is happening in the Western world may surface here as well.

WACCBIP is one of the World Bank's African Centres of Excellence (ACE) and was established in 2014. The centre has a mandate to conduct applied research into biology and pathogenesis of tropical diseases, and increase research output and innovation by enhancing collaboration among biomedical scientists and industry or private sector leaders in the sub-region.

The NMIMR works with the faculty from the department of biochemistry, cell and molecular biology of the University of Ghana with the mandate to provide masters and PhD training, as well as targeted short courses in cell and molecular biology.

See more here:
In-country genetic changes of coronavirus mapped by scientists - University World News

Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR – Columbia University Irving Medical Center

In a paper published today in the journal Cell, scientists describe unexpected, undesirable outcomes after editing genes in human embryos with CRISPR, a genomic editing system.

The study, the most detailed analysis to date of CRISPR in human embryos, shows that applying gene editing technologyto repair a blindness-causing gene early in the development of a human embryo often eliminates an entire chromosome or a large section of it.

"Our study shows that CRISPR/Cas9 is not yet ready for clinical use to correct mutations at this stage of human development, says the studys senior author Dieter Egli, assistant professor of developmental cell biology in the Department of Pediatrics at Columbia University Vagelos College of Physicians and Surgeons.

The genome editing system called CRISPR/Cas9 has revolutionized molecular biology in recent years, and its discoverers were honored with this year's Nobel Prize in chemistry. The system allows scientists to make precise changes in the genomes of cultured cells, living tissues, and animal embryos.

The first use of CRISPR in human embryos was reported in 2015. Then in 2018, He Jiankui claimed to have performed the procedure in a pair of twin embryos, eliciting a firestorm of condemnation from scientists and government officials worldwide.

In the new paper, Egli and his colleagues tested CRISPR/Cas9 genome editing's effects on early-stage human embryos carrying a mutation in a gene called EYS (eyes shut homolog), which causes hereditary blindness.

We know from previous studies in differentiated human cells and in mice that a break in the DNA results in mostly two outcomes: precise repair or small local changes. At the EYS gene, these changes can yield a functional gene, though it is not a perfect repair, says Michael Zuccaro, a research scientist at Columbia University Vagelos College of Physicians and Surgeons and co-lead author of the paper.

When Zuccaro, Egli, and their colleagues looked at the entire genomes of the modified embryos in this study, they identified another outcome. We learned that in human embryonic cells, a single break in the DNA can result in a third outcomethe loss of an entire chromosome or sometimes a large segment of that chromosome, and this loss of the chromosome is very frequent, says Zuccaro.

In 2017, a study reported the successful correction of a heart disease-causing mutation in normal human embryos using CRISPR. Comprehensive data from the new study offer a different interpretation of these results: Instead of being corrected, the chromosome carrying the mutation may have been lost altogether.

"If our results had been known two years ago, I doubt that anyone would have gone ahead with an attempt to use CRISPR to edit a gene in a human embryo in the clinic," Egli says.Our hope is that these cautionary findings should discourage premature clinical application of this important technologybut can also guide responsible research to achieve its ultimate safe and effective use.

Link:
Study Identifies Pitfall for Correcting Mutations in Human Embryos with CRISPR - Columbia University Irving Medical Center

Singapore scientists discover a new immune pathway resulting in immunodeficiency – BSA bureau

The novel pathway can be a target for liver disease and cancer drugs that failed trials due to inflammatory side effects

Scientists from Singapores A*STARs Institute of Molecular and Cell Biology (IMCB), in collaboration with doctors from KK Womens and Childrens Hospital (KKH), have discovered a new immune pathway based on an investigation of severe immunodeficiency caused by a novel mutation in the NFKBIA gene. The findings were published inThe Journal of Clinical Investigation.

A recent investigation with a rare primary immunodeficiency disease involving a two-week old infant with recurrent infections alongside lung, skin and liver damage instigated the discovery. Scientists at A*STAR identified a new genetic variant in NFKBIA that changed the levels of soluble proteins called cytokines, produced by white blood cells to drive inflammation. Abnormally high production of one cytokine, IL-1, was identified as the key derangement. Crucially, the clinical team was able suppress the patients disease by rational administration of the IL-1-blocking drug, Anakinra, based on these scientific results.

The research team, along with Singapore Immunology Network (SIgN) discovered a previously unknown pathway, which controls IL-1 production. By replicating the mutation in pre-clinical and cellular models, experimental results conclusively showed that the patients genetic variant was the cause of IL-1 hyper-production, and hence the disease. These findings have implications for the development of treatments against liver disease and cancer that target this novel pathway.

While other mutations in NFKBIA have been reported before to cause disease, this mutation has never before been identified. It is the only mutation in which hyper-production of IL-1, severe liver cholestasis and systemic inflammation were documented. The research team believes the mutation limits immune responses via the suppression of many pro-inflammatory cytokines. Yet at the same time, it causes over-production of IL-1, leading to liver damage and inflammation. Using this bedside-to-bench approach of identifying the underlying genetic causes of immunodeficiency diseases, previously unknown pathways which control immune responses can be revealed. These then serve as targets for personalised treatment strategies," said Dr John Connolly, a Research Director at IMCB and co-corresponding author of the study.

The research team will further examine which new mediators are responsible for controlling IL-1 production by this genetic variant, given that this regulatory association between the protein encoded in NFKBIA and IL-1 was not observed previously. As this novel pathway has also been a popular target for cancer drugs that failed trials due to inflammatory side effects, the team will investigate whether these new mediators are responsible for the failure of these drugs, and determine if the side effects can be circumvented.

Image Caption:Staining for the signalling protein NFB (green) in skin cells from a healthy individual (left) and the patient (right) after immune stimulation. The patients novel NFKBIA variant impairs entry of NFB into nucleus (blue). This defect led to changes in cytokine production, resulting in both immunodeficiency and multi-organ damage.

Read the original here:
Singapore scientists discover a new immune pathway resulting in immunodeficiency - BSA bureau

UNM recognized in U.S. News & World Report’s 2021 Best Global Universities rankings – UNM Newsroom

The University of New Mexico was ranked No. 256 in the recently released U.S. News & World Reports 2021 Best Global Universitiesrankings. The rankings, now in its seventh year, evaluate nearly 1,500 research universities across 86 countries on academic research and reputation.

This year's edition includes schools from 86 countries, up from 81 last year. The U.S. has the most universities in the overall ranking with 255, followed by China (176), United Kingdom (87), France (70) and Germany (68).

The Best Global Universities methodology places significant emphasis on academic research," said Robert Morse, chief data strategist at U.S. News. "With rankings by subject, region and country, students and their families can easily learn more about schools based on their specific needs and interests."

UNM is the highest ranked institution in the state and also fares well in the west region overall. The University of Colorado-Boulder (No. 59), University of Arizona (No. 97), University of Utah (No. 142) and Arizona State (No. 146) are a few of the notable institutions ahead of UNM. A few other institutions of interest include Colorado State (No. 280), Texas Tech (No. 435) San Diego State (No. 614), Utah State (No. 706), Wyoming (No. 726), and BYU (No. 748). Other state institutions include New Mexico State (No. 750). While New Mexico Tech was unranked.

In addition to the overall rankings, the new edition includes country, regional and subject-specific rankings, such as engineering, economics and business, and computer science.Ten new subject rankings were added this year, for a total of 38. The new subjects are biotechnology and applied microbiology; cell biology; chemical engineering; endocrinology and metabolism; energy and fuels; gastroenterology and hepatology; infectious diseases; nanoscience and nanotechnology; public, environmental and occupational health; and radiology, nuclear medicine and medical imaging.

UNM was highly-recognized in the following subject rankings:

Based onWeb of Sciencedata andInCitesmetrics provided by Clarivate, a global leader in providing trusted information and insights to accelerate the pace of innovation, the Best Global Universitiesmethodologyweighs factors that measure a university's global and regional research reputation and academic research performance. For the overall rankings, this includes bibliometric indicators such as publications, citations and international collaboration. Each subject ranking has its own methodology based on academic research performance in that specific area.

"The coronavirus pandemic has introduced additional factors to consider when pursuing higher education, especially if you're looking to earn a degree abroad," said Anita Narayan, managing editor of Education at U.S. News. "For prospective students, the Best Global Universities rankings provide a solid place to begin your search, create an initial list of schools and compare overall academic quality.

The Best Global Universities rankings serve the broader U.S. News mission of providing trusted information and rankings such asBest Colleges,Best Graduate SchoolsandBest Online Programs to help students navigate their higher education options.

For a full list of the global and subject rankings, visit 2021 Best Global Rankings.

View original post here:
UNM recognized in U.S. News & World Report's 2021 Best Global Universities rankings - UNM Newsroom